Inoue Y, Emoto M, Inoue H, Kaku K, Kaneko T
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Japan.
Eur J Pharmacol. 1995 Sep 15;284(1-2):77-82. doi: 10.1016/0014-2999(95)00368-u.
The specific binding sites for sulfonylureas in the rat liver membrane fraction were demonstrated and characterized. [3H]Glibenclamide binding to the liver membrane was specific, time- and temperature-dependent, and reversible. Scatchard analysis showed a single class binding site. The dissociation constant (Kd) for glibenclamide was 1.1 microM and the binding capacity (Bmax) was 50 pmol/mg protein. [3H]Glibenclamide binding could be displaced by other sulfonylureas. Half-maximal inhibition of binding (IC50) for glimepiride, gliclazide, acetohexamide, tolbutamide and chlorpropamide was 4.2 microM, 74 microM, 0.33 mM, 0.60 mM, 1.2 mM, respectively. Each value is close to the reported blood concentration when a therapeutic dose of each drug is administered orally. The order of IC50 values is coincident with the order of potency of the clinical hypoglycemic effect of these drugs. We had shown that these concentrations of sulfonylureas stimulate 6-phosphofructo-2-kinase in the liver or hepatocytes and inhibit phosphoenolpyruvate carboxykinase in the hepatoma cells. The specific binding sites demonstrated here may play some roles when sulfonylureas affect carbohydrate metabolism in the liver.
已证实并鉴定了大鼠肝膜组分中磺脲类药物的特异性结合位点。[3H]格列本脲与肝膜的结合具有特异性、时间和温度依赖性,且是可逆的。Scatchard分析显示存在单一类型的结合位点。格列本脲的解离常数(Kd)为1.1微摩尔,结合容量(Bmax)为50皮摩尔/毫克蛋白质。[3H]格列本脲的结合可被其他磺脲类药物取代。格列美脲、格列齐特、醋磺己脲、甲苯磺丁脲和氯磺丙脲对结合的半数抑制浓度(IC50)分别为4.2微摩尔、74微摩尔、0.33毫摩尔、0.60毫摩尔、1.2毫摩尔。当口服给予每种药物的治疗剂量时,每个值都接近报告的血药浓度。IC50值的顺序与这些药物临床降血糖作用的效力顺序一致。我们已表明,这些浓度的磺脲类药物可刺激肝脏或肝细胞中的6-磷酸果糖-2-激酶,并抑制肝癌细胞中的磷酸烯醇丙酮酸羧激酶。此处显示的特异性结合位点在磺脲类药物影响肝脏碳水化合物代谢时可能发挥一些作用。